CoChat
Sign Up
Cited by 141Diabetes Treatment and ManagementPancreatitis Pathology and TreatmentPancreatic function and diabetes

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Exenatide (Exendin-4)–Induced Pancreatitis

Denker, Paul S., Dimarco, Paul E.·2006·Diabetes Care
DOI 10.2337/diacare.29.02.06.dc05-2043
Open this paper in CoChat — free account

Abstract

Exenatide is a 39–amino acid peptide approved for the adjunctive treatment of type 2 diabetes. It is an incretin mimetic agent that is consistent in activity with the actions of glucagon-like peptide 1. Proposed mechanisms of action include enhanced glucose-dependent insulin secretion from pancreatic β-cells, restoration of first-phase insulin response, suppression of glucagon secretion, and delay of gastric emptying. Kendall et al. (1) found no evidence of cardiovascular, pulmonary, hepatic, or renal toxicities with exenatide. Nausea (39–48%) and hypoglycemia (19–27%) were the most common side effects reported. A 69-year-old man with type 2 diabetes of 15 years’ duration presented for follow-up. He had known diabetic neuropathy and retinopathy. His medical history was remarkable for coronary artery disease, gastroesophageal reflux disease, rheumatoid arthritis, and …

Overview

Integrity signals

Registry

Crossref · 10.2337/diacare.29.02.06.dc05-2043

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 1 references

Cited by

Sorted by citations

See all 141

Related

Metadata

Authors
Denker, P. S., & Dimarco, P. E.
Affiliations
Largo HCA Diabetes Center, Clearwater, Florida
Venue
Diabetes Care
Publisher
American Diabetes Association
Published
2006-02-01
Volume
29
Issue
2
Pages
471-471
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
DOI
10.2337/diacare.29.02.06.dc05-2043
OpenAlex
W2029214914
Cited by
140
References
1
Citations by year
2026: 1 · 2025: 3 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 8 · 2015: 9 · 2014: 17 · 2013: 15 · 2012: 12
FWCI
6.21
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
exenatide, exendin-4, pancreatitis, type 2 diabetes, incretin mimetics, glucagon-like peptide-1, adverse drug reactions, drug-induced pancreatitis
MeSH terms
Exenatide, Acute Disease, Aged, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Male, Pancreatitis, Peptides, Venoms, Abdominal Pain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review